WaveMan
WaveMan · Company
RFL · Rafael Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

RFL Rafael (RFL) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001713863
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
20
13F, latest reported quarter

Rafael insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Rafael Holdings, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
JONAS HOWARD S
Exec Chairman, CEO & President
BUY
2025-06-09 SECtraded 2025-06-05
324,219
$415.0K
-58.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (2 buys, 3 sales), the last on Aug 9, 2022.
  • -44.7% median (-44.7% mean) 90-day return after 2 previous buys.
  • The trade is 100.0% of the 324,219 shares held after it.
  • No other insider bought within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Exec Chairman, CEO & President JONAS HOWARD S bought about $415.0K of RFL on Jun 5, 2025, the largest insider purchase at the company since 2022; 20 funds added in the latest 13F quarter.
JONAS HOWARD S
Exec Chairman, CEO & President
BUY
2025-06-09 SECtraded 2025-06-05
12,299,207
$15.7M
-58.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (2 buys, 3 sales), the last on Aug 9, 2022.
  • -44.7% median (-44.7% mean) 90-day return after 2 previous buys.
  • The trade is 100.0% of the 12,299,207 shares held after it.
  • No other insider bought within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Exec Chairman, CEO & President JONAS HOWARD S bought about $15.7M of RFL on Jun 5, 2025, the largest insider purchase at the company on our record; 20 funds added in the latest 13F quarter.
JONAS HOWARD S
Exec Chairman, CEO & President
BUY
2025-06-09 SECtraded 2025-06-05
457,031
$585.0K
-58.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (2 buys, 3 sales), the last on Aug 9, 2022.
  • -44.7% median (-44.7% mean) 90-day return after 2 previous buys.
  • The trade is 100.0% of the 457,031 shares held after it.
  • No other insider bought within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Exec Chairman, CEO & President JONAS HOWARD S bought about $585.0K of RFL on Jun 5, 2025, the largest insider purchase at the company since 2022; 20 funds added in the latest 13F quarter.
JONAS HOWARD S
Executive Chairman
SELL
2022-08-09 SEC
64,674
$119.0K
-42.2%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (2 buys, 2 sales), the last on Aug 8, 2022.
  • -44.7% median (-44.7% mean) 90-day return after 2 previous buys.
  • The trade is 2.0% of the 3,225,806 shares held after it.
  • 1 other insider sold within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman JONAS HOWARD S sold about $119.0K of RFL on Aug 9, 2022, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 20 funds added in the latest 13F quarter.
i9 PLUS, LLC
SELL
2022-08-09 SEC
64,674
$119.0K
-42.2%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 8, 2022.
  • The trade is 2.0% of the 3,225,806 shares held after it.
  • 1 other insider sold within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider i9 PLUS, LLC sold about $119.0K of RFL on Aug 9, 2022, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 20 funds added in the latest 13F quarter.
11 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 6 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
20 funds bought in last quarter
below 68% of Pharma & Biotech
Revenue
-95.3% year over year
below 90% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.1% of the float short (float per yahoo 2026-10-27) · 2.7 days to cover · settled 2026-10-15
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch RFL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-13.2%12M
-15%+50%+114%+178%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RFL: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
1,365,997 sh
$4.5M
GEODE CAPITAL MANAGEMENT, LLC
429,879 sh
$1.4M
BlackRock, Inc.
390,068 sh
$1.3M
DIMENSIONAL FUND ADVISORS LP
278,910 sh
$914.7K
VANGUARD FIDUCIARY TRUST CO
206,521 sh
$677.4K

Congress trades in RFL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RFL planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

RFL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$356.3K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$23.6K position · as of 2026-06-30
0.0%
U.S. MICRO CAP PORTFOLIO
$179.9K position · as of 2026-07-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$1.6M position · as of 2026-06-30
0.0%
JNL/DFA U.S. Small Cap Fund
$13.6K position · as of 2026-06-30
0.0%
Dimensional US Vector Equity ETF
$6.6K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 20 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RFL financials

Revenue growth
-95.3%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$980.0K
four quarters, 2025-05-01 to 2026-04-30
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.49x
long-term 2019-07-31 (82 months older than the period end) plus current 2024-03-13 (25 months older than the period end); equity 2026-04-30
Cash flow to debt
-0.87x
TTM operating cash flow over long-term 2019-07-31 (82 months older than the period end) plus current 2024-03-13 (25 months older than the period end)
Return on equity
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on assets
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-40.9%
operating income (EBIT proxy) over average of 2025-04-30 and 2026-04-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$6.3M
market value at close 2026-10-26 on 2018-03-12 shares, plus long-term 2019-07-31 (82 months older than the period end) plus current 2024-03-13 (25 months older than the period end), minus cash 2026-04-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-072024-072023-072022-07
Revenue$917.0K$637.0K$279.0K$410.0K
Operating income-$29.2M-$102.6M-$15.0M-$60.5M
Net income-$30.5M-$34.4M-$1.9M-$124.7M
EPS (diluted)-1.04-1.45-0.08-6.31
Operating cash flow-$18.9M-$7.8M-$10.9M-$26.1M
Cash$52.8M$2.7M$21.5M$26.5M
SEC XBRL, fiscal years, as known on 2026-10-28

RFL Stock Sonar score 4/7 axes

Find similar shapesCompare

RFL ranks highest on risk and compliance (54th percentile) and financial health (43rd), and lowest on growth (10th), among Pharma & Biotech peers.

Financial health
43
Inputs
  • Debt to equity0.49x · 32 pct, sector of 352
  • Cash flow to debt-0.87x · 55 pct, sector of 371
Growth
10
Inputs
  • Revenue growth, YoY-95.3% · 10 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
24
Inputs
  • Funds adding, latest quarter20 · 32 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$72K · 15 pct, sector of 133
Risk and compliance
54
Inputs
  • Short interest, % of float+1.1% · 79 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+15.3% · 29 pct, sector of 511
3 not measured: Profitability, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: pre-tax loss, no effective tax rate to apply; the filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies